20 completed, 3 recruiting, 3 unknown, 2 terminated. 30 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 30 | Completed 20, Recruiting 3, Unknown 3, Terminated 2, Active not recruiting 1, Not yet recruiting 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 2 | Completed 1, Unknown 1 |
Follow Febuxostat: new trials by email Literature Review of Febuxostat trials Research Report on Febuxostat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Boosting Osimertinib Blood Brain Barrier Penetration Osimertinib & febuxostat - Non-Small Cell Lung Cancer | Phase 2 | Recruiting | Maastricht University Medical Center | 7 | 2026-06-01 | 2026-06-05 |
| Clinical Trial of BR2251 Tablets for Patients With Primary Gout and Hyperuricemia BR2251, Febuxostat - Gout and Hyperuricemia | Phase 2 | Not yet recruiting | BioRay Pharmaceutical Co., Ltd. | 160 | 2026-04-01 | 2026-03-27 |
| The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia SHR4640 ï¼›Febuxostat, SHR4640 ; Febuxostat, SHR4640 - Primary Gout and Hyperuricemia | Phase 2 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 340 | 2026-02-09 | 2026-04-07 |
| Clinical Study to Evaluate the Efficacy of Febuxostat in the Treatment of Conservatively Managed Intracranial Hemorrhage Patients Febuxostat 40 mg, Standard medical treatment - Intracranial Hemorrhage | Phase 2 | Recruiting | Tanta University | 46 | 2025-11-20 | 2026-07-15 |
| Comparative Clinical and Biochemical Study Evaluating the Effectiveness of Metformin Versus Febuxostat on Gouty Obese Non-Diabetic Patients Febuxostat Tablets, Metformin - Gout | Phase 2 | Completed | Mostafa Bahaa | 60 | 2025-05-30 | 2026-09-17 |
| A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects Febuxostat, IBI128 - Gout, Hyperuricemia | Phase 2 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 84 | 2024-07-10 | 2025-03-27 |
| Phase II/III Study of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and Hyperuricemia Febuxostat 20MG Tablets, Febuxostat 20MG Placebo, AR882 25MG - Primary Gout, Hyperuricemia | Phase 2 / Phase 3 | Unknown | Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd | 636 | 2024-04-22 | 2024-09-19 |
| Clinical Study of SHR4640 Tablets Combined With Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia SHR4640 tablet, febuxostat tablet, SHR4640 placebo tablet - Primary Gout and Hyperuricemia | Phase 2 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 129 | 2022-09-15 | 2022-08-24 |
| Comparative Study Between Febuxostat Versus Vitamin E in Non-alcoholic Steatohepatitis Patients With Hyperuricemia Febuxostat 80 MG Oral Tablet, vit E - Non Alcoholic Steatohepatitis, Hyperuricemia | Phase 2 | Active not recruiting | Tanta University | 70 | 2022-08-25 | 2025-01-23 |
| Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients Group 1: AR882 Alone and in Combination with Febuxostat (FBX), Group 2: AR882 Alone and in Combination with Allopurinol (ALLO) - Gout Patients | Phase 2 | Completed | Arthrosi Therapeutics | 30 | 2020-02-03 | 2020-11-19 |
| Effect of Allopurinol or Febuxostat to Prevent Contrast Induced Acute Kidney Injury (CI-AKI) Allopurinol, Febuxostat, Placebo - Contrast-induced Nephropathy, Contrast-induced Acute Kidney Injury | Phase 2 | Unknown | Instituto Nacional de Cardiologia Ignacio Chavez | 558 | 2018-12-05 | 2018-12-06 |
| A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA Verinurad, Febuxostat, Dapagliflozin - Asymptomatic Hyperuricemia | Phase 2 | Completed | AstraZeneca | 36 | 2017-10-25 | 2019-08-28 |
| Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria Verinurad 9 mg+Febuxostat 80 mg, Placebo - Hyperuricemia, Albuminuria | Phase 2 | Completed | AstraZeneca | 60 | 2017-05-18 | 2020-01-10 |
| Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults Febuxostat - Tumor Lysis Syndrome | Phase 1 / Phase 2 | Terminated | Menarini Group | 30 | 2017-02-27 | 2021-06-03 |
| Effect of Febuxostat on Endothelial Dysfunction in Hemodialysis Patients. Febuxostat, Placebo - Endothelial Dysfunction, Endstage Renal Disease | Phase 2 / Phase 3 | Completed | Ain Shams University | 57 | 2016-08-01 | 2018-01-02 |
| A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia Patients RDEA3170, Febuxostat, Benzbromarone - Gout and Asymptomatic Hyperuricemia | Phase 1 / Phase 2 | Completed | AstraZeneca | 110 | 2014-12-01 | 2015-06-12 |
| A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout Placebo, AC-201, Febuxostat - Gout | Phase 2 | Completed | TWi Biotechnology, Inc. | 127 | 2014-12-01 | 2022-06-28 |
| RDEA3170 and Febuxostat Combination Study in Gout Subjects RDEA3170 15 mg, RDEA3170 10 mg, RDEA3170 2.5 - Gout | Phase 2 | Completed | Ardea Biosciences, Inc. | 64 | 2014-10-01 | 2017-07-27 |
| Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout Arhalofenate, Febuxostat, Colchicine - Gout, Hyperuricemia | Phase 2 | Completed | Gilead Sciences | 32 | 2014-08-01 | 2026-09-18 |
| Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment Febuxostat IR, Febuxostat XR, Febuxostat placebo - Gout, Moderate Renal Impairment | Phase 2 | Completed | Takeda | 189 | 2014-05-01 | 2016-11-03 |
Showing 20 of 30. Sign in to see all of them.
Gout (17) · Hyperuricemia (15) · Albuminuria (1) · Angina Pectoris (1) · Arthritis, Gouty (1) · Carcinoma, Non-Small-Cell Lung (1) · Diabetes Mellitus, Type 2 (1) · Hematologic Neoplasms (1) · Hypertension (1) · Intracranial Hemorrhages (1) · Kidney Calculi (1) · Nephrolithiasis (1) · Non-alcoholic Fatty Liver Disease (1) · Renal Insufficiency (1) · Tumor Lysis Syndrome (1)
Takeda (8) · AstraZeneca (3) · Gilead Sciences (2) · Jiangsu HengRui Medicine Co., Ltd. (2) · TWi Biotechnology, Inc. (2) · Tanta University (2) · Ain Shams University (1) · Ardea Biosciences, Inc. (1) · Arthrosi Therapeutics (1) · BioRay Pharmaceutical Co., Ltd. (1) · Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd (1) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Instituto Nacional de Cardiologia Ignacio Chavez (1) · Maastricht University Medical Center (1) · Menarini Group (1)
United States (12) · China (3) · Egypt (3) · Taiwan (2) · Bulgaria (1) · Hungary (1) · Italy (1) · Japan (1) · Mexico (1) · Netherlands (1) · New Zealand (1) · Spain (1)
Alexandra Steinberg, MD, PhD (1) · Chang-Youh Tsai (1) · Christopher Wynne, MBChB, Grad Dip Pharm Med (1) · Franco Locatelli, Prof, MD (1) · J. Hall (1) · Magdalena Madero, MD (1)
PMID 16911575, PMID 32951150, PMID 15751090, PMID 19141576, PMID 21169856, PMID 21572152, PMID 23929928, PMID 26894653, PMID 27980008, PMID 28975718, PMID 29102979, PMID 29657831, PMID 29848361, PMID 29868853, PMID 33075806, PMID 33130235, PMID 34383954, PMID 40383220
2016 (1), 2025 (1)